LACTULOSE SOLUTION, USP

Manufacturer
Aidarex Pharmaceuticals LLC
Effective date
2013-10-02
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:18:05

Label at a glance#

ProductLactulose
Active ingredientLACTULOSE
Label structure12 sections

Indications and uses

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

Dosage and administration

The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement. Note: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water or milk.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

FOR ORAL ADMINISTRATION

DESCRIPTION

DESCRIPTION SECTION

Lactulose is a synthetic disaccharide in solution form for oral administration. Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 1.2 g or less of other sugars). Also contains water. The pH range is 4.8 to 6.0.

Lactulose is a colonic acidifier which promotes laxation.

The chemical name for lactulose is 4-O-β-D-galactopyranosyl-D-fructofuranose. The molecular formula is C12H22O11. t has the following structural formula:

Lactulose Formula
Lactulose Formula

The molecular weight is 342.30. It is freely soluble in water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Lactulose is poorly absorbed from the gastrointestinal tract and no enzyme capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue. As a result, oral doses of lactulose reach the colon virtually unchanged. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool.

Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24 to 48 hours may be required to produce the desired bowel movement.

Lactulose given orally to man and experimental animals resulted in only small amounts reaching the blood. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Since lactulose solution contains galactose (less than 1.6 g/15 mL), it is contraindicated in patients who require a low galactose diet.

WARNINGS

WARNINGS SECTION

A theoretical hazard may exist for patients being treated with lactulose solution who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO2 as an additional safeguard may be pursued but is considered to be a redundant measure.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Since lactulose solution contains galactose (less than 1.6 g/15 mL) and lactose (less than 1.2 g/15 mL) it should be used with caution in diabetics.

Information for Patients

SPL UNCLASSIFIED SECTION

In the event that an unusual diarrheal condition occurs, contact your physician.

Laboratory Tests

SPL UNCLASSIFIED SECTION

Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

Drug Interactions

SPL UNCLASSIFIED SECTION

Results of preliminary studies in humans and rats suggest that non-absorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution.

Carcinogenesis, Mutagenesis, Impairment of Fertility

SPL UNCLASSIFIED SECTION

There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.

There are no known animal data on long-term potential for mutagenicity.

Administration of lactulose solution in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity.

In studies of mice, rats, and rabbits, doses of lactulose solution up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition.

Pregnancy

SPL UNCLASSIFIED SECTION

Teratogenic Effects

SPL UNCLASSIFIED SECTION

Pregnancy category B. Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

SPL UNCLASSIFIED SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose solution is administered to a nursing woman.

Pediatric Use

SPL UNCLASSIFIED SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Precise frequency data are not available.

Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.

Nausea and vomiting have been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Signs And Symptoms:

SPL UNCLASSIFIED SECTION

There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.

Oral LD50: The acute oral LD50 of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats.

Dialysis: Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.

Note: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water or milk.

HOW SUPPLIED

HOW SUPPLIED SECTION

Lactulose Solution USP 10 g/15 mL is available as follows:

32 fl oz (946 mL) bottle

Lactulose Solution contains lactulose 667 mg/mL (10 g/15 mL).

Store at controlled room temperature 15°-30°C (59° to 86°F). Do not freeze.

Under recommended storage conditions, a normal darkening of color may occur. Such darkening is characteristic of sugar solutions and does not affect therapeutic action. Prolonged exposure to temperatures above 86°F (30°C) or to direct light may cause extreme darkening and turbidity which may be pharmaceutically objectionable. If this condition develops, do not use.

Prolonged exposure to freezing temperatures may cause change to a semi-solid, too viscous to pour. Viscosity will return to normal upon warming to room temperature.

Dispense in original container or in a tight, light-resistant container as defined in the USP, with a child-resistant closure.

Rx only

Distributed by:

Hi-Tech Pharmacal Co., Inc.

Amityville, NY 11701

MG #9201

Repackaged By :
Aidarex Pharmaceuticals LLC,
Corona, CA 92880

Rev. 779:04 3/10

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

IMAGE LABEL
IMAGE LABEL

NDC 53217-0009-01

LACTULOSE SOLUTION, USP

10 g/15 mL

INDICATIONS: For the treatment of constipation. See attached insert labeling for full information.

Rx only

32 fl oz (946 mL)

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
391937lactulose 10 GM in 15 mL Oral SolutionPSN1
391937lactulose 667 MG/ML Oral SolutionSCD1
391937lactulose 10 GM per 15 ML Oral SolutionSY1
391937lactulose 20 GM per 30 ML Oral SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
LACTULOSE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
13620a32-e3b4-4aad-8280-283dce30ddffProduct name120260105
27883b46-af31-44b0-b4ce-e6b4f6d825a7Product name420250812
c1a80c95-0e51-52a0-75fa-75808f51ded8Product name220150421

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
53217-009-012020-01-31C16284748780-19d75b9d0-cd75-f424-e053-dadaa90a57ceLACTULOSE SOLUTION, USP

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
53217-009-01Lactulose946 mL in 1 BOTTLE, PLASTICSOLUTION9461

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
53217-009LACTULOSE SOLUTION [AIDAREX PHARMACEUTICALS LLC]1Legacy NDC, 1 package rows20140214_a5a5747b-5194-43a9-8307-f1e05c6eacb4.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
53217-009-01ML - Milliliter53217-009c96f29ce-5cd1-4e10-b23b-f2493e83dc7012015-10-02
50383-779-08ML - Milliliter50383-779fde82a52-aa05-4816-8685-c9ff286429df12012-07-24
50383-779-15ML - Milliliter50383-779d29ee989-30d6-4102-ad6d-609458b9908312012-07-24
50383-779-16ML - Milliliter50383-779c348a4fa-126e-458b-87c9-933e9e6ef54d12012-07-24
50383-779-17ML - Milliliter50383-779f3900f5f-ad8a-437a-99ff-47000c02a24812013-05-02
50383-779-30ML - Milliliter50383-77914c0cd30-345a-41b8-9f30-f6ff5b5f5d3a12012-07-24
50383-779-31ML - Milliliter50383-77928c7648a-ae73-4704-87f7-57bb22f0dd6d12013-05-02
50383-779-32ML - Milliliter50383-779548dec33-f807-4a61-96b7-30344bf46b7c12012-07-24
50383-779-33ML - Milliliter50383-779fe2b6e67-526f-4524-93af-209ecdce0d6312013-05-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
LACTULOSEACTIVE INGREDIENT9U7D5QH5AE1
LACTULOSEACTIVE MOIETY9U7D5QH5AE1
GALACTOSEINACTIVE INGREDIENTX2RN3Q8DNE1
LACTOSEINACTIVE INGREDIENTJ2B2A4N98G1
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I1
WATERINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
53217-00953217-009-01
50383-779

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 214 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER, FOR SUSPENSION / ORAL9 mgExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GGRANULE, FOR SUSPENSION / ORAL512.5 mg/5mlExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, EMULSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY, METERED / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAPERITONEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / RECTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBMUCOSALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IELIXIR / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GSOLUTION / ORAL1682 mg/15mlExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, DELAYED RELEASE / ORAL4 mgExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS133 mgExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / SUBMUCOSALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBARACHNOIDADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GPOWDER, FOR SOLUTION / ORALNAExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGRANULE, FOR SUSPENSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-ARTERIAL176 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IENEMA / RECTAL0.44 %v/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IJELLY / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GOINTMENT / TOPICALNAExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, DELAYED RELEASE / ORAL0.25 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET, CHEWABLE / ORAL1412 mgExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET / ORAL10 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INFILTRATIONADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICREAM, AUGMENTED / TOPICAL6 mgExact identifier — unii candidate
174 equally ranked IID candidates
GALACTOSEGALACTOSEX2RN3Q8DNETABLET / ORAL0.67 mgExact identifier — unii candidate
4 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER, FOR SOLUTION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER, FOR SUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET, SUGAR COATED / ORALNAExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IAEROSOL, METERED / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GCONCENTRATE / ORALNAExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, COATED / ORALNAExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET / SUBLINGUAL352 mgExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL / OPHTHALMIC6 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, COATED / ORAL0.08 mgExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GCREAM / VAGINAL3 %w/wExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION/ DROPS / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / ENDOTRACHEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET, DELAYED RELEASE / ORAL160 mgExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, LIQUID FILLED / ORAL1.5 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRATUMORADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAOCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
GALACTOSEGALACTOSEX2RN3Q8DNESOLUTION / ORAL2200 mg/15mlExact identifier — unii candidate
4 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET / RECTAL20 mgExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, FILM COATED / ORAL8 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / EXTRACORPOREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / EPIDURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IAEROSOL, FOAM / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074076-001LACTULOSELACTULOSE10GM/15MLSOLUTION / ORAL1995-07-03

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-0384e616aacf4f…
2026-08-18 06:07:402026-07A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-03caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-03011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-0331067a03dcf5…
2025-08-23 18:47 UTC2025-08A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-036a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-03fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-03b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-0303ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-032680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-035bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-03d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-03d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-0379d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-03301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-031e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074076-001LACTULOSE10GM/15MLSOLUTION / ORAL1995-07-038072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-035c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-035d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-034b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-0374a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-0387673890dc5c…
2021-03-12 10:30 UTC2021-03A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-035aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-038869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-033f01610625f2…
2019-09-15 20:21 UTC2019-09A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03b00525d2431f…
2019-07-19 19:46 UTC2019-07A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-036a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-031c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-039b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-033f0d92c62455…
2023-05-13 08:27 UTC2023-05A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03053a50430f4f…
2023-01-26 05:58 UTC2023-01A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-033bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-033a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074076-001LACTULOSE10GM/15MLSOLUTION / ORALAARS1995-07-03f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074076-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074076-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074076-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074076-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074076-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074076-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074076-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A074076-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074076-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074076-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074076-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A074076-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A074076-001AA1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074076-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074076-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074076-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074076-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074076-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074076-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074076-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A074076-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A074076-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074076-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074076-001AA1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A074076-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A074076-001AA1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
9be2d0a1-1415-47de-87f0-03a66680c62fa5a5747b-5194-43a9-8307-f1e05c6eacb42013-10-02Warnings, Adverse reactionsExact identifier
spl id: 9be2d0a1-1415-47de-87f0-03a66680c62f
spl set id: a5a5747b-5194-43a9-8307-f1e05c6eacb4

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.